Roth Capital analyst Ed Arce reiterated a Buy rating on Conatus Pharmaceuticals (NASDAQ:CNAT) with a price target of $19, which represents a potential …
In a research report released today, MLV analyst Vernon Bernardino maintained a Buy rating on Conatus Pharmaceuticals (NASDAQ:CNAT) with a $16 price target, as …
In a research report published today, MLV analyst Vernon Bernardino initiated a coverage on shares of Conatus Pharma (NASDAQ:CNAT) with a Buy rating …
In a research note published August 14, Roth Capital analyst Ed Arce affirmed a Buy rating on shares of Conatus Pharmaceuticals (CNAT) with a $19.00 price target, following the company’s …
In a report published today, Roth Capital analyst Ed Arce resumed coverage on Conatus Pharmaceuticals Inc. (CNAT) with a Buy rating and $19.
